Successful immunosuppressive treatment of chyloperitoneum in the newborn infant with multiple congenital anomalies

A unique clinical case of a combination of malformations of the anterior abdominal wall (omphalocele of large size) and malformation of the lymphatic system (congenital chyloperitoneum) is presented. Each of these defects can lead to a fatal outcome, and the combination of them has greatly increased the risk of developing an unfavourable outcome. The use of immunosuppressive therapy with Sirolimus used for the first time during the newborn period made it possible to completely stop the chyloperitoneum. This clinical example shows that in the treatment of surgical patients with multiple congenital malformations, a multidisciplinary approach and observation is necessary for timely response to the patient’s condition.

Contribution:
Gurskaya A.S. — concept and design;
Nakovkin O.N., Akhmedova D.M., Karnuta I.V., Shchukina A.A., Petrova N.V., Skvortsova V.A., Sulavko M.A., Ekimovskaya E.V. — collection and processing of the material;
Gurskaya A.S., Sulavko M.A. — writing the text;
Fisenko A.P. — editing.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: August 24, 2022
Accepted: September 20, 2022
Published: October 31, 2022

1. Shchukina A.A., Mokrushina O.G., Gurskaya A.S., D’yakonova E.Yu. Current issues of diagnosis and treatment of neonatal omphalocele. Rossiyskiy pediatricheskiy zhurnal. 2020; 23(2): 126–31. https://doi.org/10.18821/1560-9561-2020-23-2-126-131 (in Russian)

2. Roux N., Grangé G., Salomon L.J., Rousseau V., Khen-Dunlop N., Beaudoin S. Early diagnosis of omphalocele: Prognostic value of the herniated viscera for associated anomalies. Gynecol. Obstet. Fertil. Senol. 2019; 47(9): 637–42. https://doi.org/10.1016/j.gofs.2019.06.013

3. Kong C.K.Y., Zi Xean K., Li F.X., Chandran S. Umbilical cord anomalies: antenatal ultrasound findings and postnatal correlation. BMJ Case Rep. 2018; 2018: bcr2018226651. https://doi.org/10.1136/bcr-2018-226651

4. Kireeva N.B., Pivikov V.E., Novopol’tsev E.A., Tumakova N.B., Plokharskiy N.A., Biryukov Yu.P., et al. Chylothorax and chyloperitoneum in newborns: 4 case report. Rossiyskiy vestnik detskoy khirurgii, anesteziologii i reanimatologii. 2016; 6(4): 88–90. (in Russian)

5. Pessanha I., Bravo M., Piedade C., Lopes M.F. Complex lymphatic malformations in pediatrics: a review of treatment options. Minerva Pediatr. (Torino). 2022; 74(1): 70–80. https://doi.org/10.23736/S2724-5276.20.06037-5

6. Poddubnyy I.V., Syt’kov V.V., Yatsyk S.P., Smirnov I.E., Kucherov Yu.I., Rekhviashvili M.G., et al. Multidisciplinary approach in treatment of a newborn child with chylotorax. Rossiyskiy pediatricheskiy zhurnal. 2020; 23(3): 208–12. https://doi.org/10.18821/1560-9561-2020-23-3-208-212 (in Russian)

7. Rudakova E.A., Kovaleva O.A., Openysheva A.V., Koroleva M.A. Results of treatment of chyloperitoneum in a newborn children. Permskiy meditsinskiy zhurnal. 2015; 32(6): 78–83. (in Russian)

8. Marshall J., Salemi J.L., Tanner J.P., Ramakrishnan R., Feldkamp M.L., Marengo L.K., et al. Prevalence, correlates, and outcomes of omphalocele in the United States, 1995-2005. Obstet. Gynecol. 2015; 126(2): 284–93. https://doi.org/10.1097/AOG.0000000000000920

9. Honnorat M., Viremouneix L., Ayari S., Guibaud L., Coste K., Claris O., et al. Early adjuvant medication with the mTOR inhibitor sirolimus in a preterm neonate with compressive cystic lymphatic malformation. Front. Pediatr. 2020; 8: 418. https://doi.org/10.3389/fped.2020.00418

10. Adams D.M., Trenor 3rd C.C., Hammill A.M., Vinks A.A., Patel M.N., Chaudry G., et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016; 137(2): e20153257. https://doi.org/10.1542/peds.2015-3257

11. Ji Y., Chen S., Yang K., Zhou J., Zhang X., Jiang X., et al. A prospective multicenter study of sirolimus for complicated vascular anomalies. J. Vasc. Surg. 2021; 74(5): 1673–81.e3. https://doi.org/10.1016/j.jvs.2021.04.071

12. Amodeo I., Colnaghi M., Raffaeli G., Cavallaro G., Ciralli F., Gangi S., et al. The use of sirolimus in the treatment of giant cystic lymphangioma: Four case reports and update of medical therapy. Medicine (Baltimore).2017; 96(51): e8871. https://doi.org/10.1097/MD.000000000000887

13. Laforgia N., Schettini F., De Mattia D., Martinelli D., Ladisa G., Favia V. Lymphatic malformation in newborns as the first sign of diffuse lymphangiomatosis: successful treatment with sirolimus. Neonatology. 2016; 109(1): 52–5. https://doi.org/10.1159/000440939

14. Chen X., Wang D., Wang G., Huang Y., Yu X., Lu J., et al. Optimization of initial dose regimen for sirolimus in pediatric patients with lymphangioma. Front. Pharmacol. 2021; 12: 668952. https://doi.org/10.3389/fphar.2021.668952

15. Schuster S.R. A new method for the staged repair of large omphaloceles. Surg. Gynecol. Obstet. 1967; 125(4): 837–50.

16. Khvorostov I.N., Andreev D.A., Verbin O.I., Shramko V.N. The use of intestinal exteriorization technology in the treatment of congenital diaphragmatic hernia in a newborn infant. Rossiyskiy pediatricheskiy zhurnal. 2020; 23(4): 271–3. http://doi.org/10.18821/1560-9561-2020-23-4-271-273 (in Russian)

17. Bielicki I.N., Somme S., Frongia G., Holland-Cunz S.G., Vuille-Dit-Bille R.N. Abdominal wall defects-current treatments. Children (Basel). 2021; 8(2): 170. https://doi.org/10.3390/children8020170

18. Schmedding A., Wittekind B., Salzmann-Manrique E., Schloesser R., Rolle U. Decentralized surgery of abdominal wall defects in Germany. Pediatr. Surg. Int. 2020; 36(5): 569–78. https://doi.org/10.1007/s00383-020-04647-7

19. Donyush E.K., Kondrashova Z.A., Polyaev Yu.A., Garbuzov R.V. Sirolimus for the treatment of vascular anomalies in children. Rossiyskiy zhurnal detskoy gematologii i onkologii. 2020; 7(3): 22–31. https://doi.org/10.21682/2311-1267-2020-7-3-22-31 (in Russian)

20. Ilaria A., Mariarosa C., Genny R., Giacomo C., Fabrizio C., Silvana G., et al. The use of sirolimus in the treatment of giant cystic lymphangioma: Four case reports and update of medical therapy. Medicine (Baltimore). 2017; 96(51): e8871. https://doi.org/10.1097/MD.0000000000008871

21. Cîrstoveanu C., Bizubac A.M., Mustea C., Manolache Ș., Istrate-Bârzan A., Sfrijan D., et al. Antiproliferative therapy with sirolimus and propranolol for congenital vascular anomalies in newborns (Case reports). Exp. Ther. Med. 2021; 22(4): 1097. https://doi.org/10.3892/etm.2021.10531

22. Serio J., Gattoline S., Collier H., Bustin A. Evaluation of sirolimus dosing in neonates and infants with lymphatic disorders: a case series. J. Pediatr. Pharmacol. Ther. 2022; 27(5): 447–51. https://doi.org/10.5863/1551-6776-27.5.447

23. Sandbank S., Molho-Pessach V., Farkas A., Barzilai A., Greenberger S. Oral and topical sirolimus for vascular anomalies: a multicentre study and review. Acta Derm. Venereol. 2019; 99(11): 990–6. https://doi.org/10.2340/00015555-3262

24. Scuglia M., Conforti A., Valfrè L., Totonelli G., Iacusso C., Iacobelli B.D., et al. Operative management of neonatal lymphatic malformations: lesson learned from 57 consecutive cases. Front. Pediatr. 2021; 9: 709223. https://doi.org/10.3389/fped.2021.709223